Isolated Mitochondria Composition for Tendon Cell Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tendinopathy are temporary and lack a fundamental solution, with existing therapies providing only short-term relief and potential harm to soft tissues.
Innovation Solution
A pharmaceutical composition comprising isolated mitochondria as an active ingredient, administered to restore ATP synthesis and antioxidant capacity, inhibit apoptotic factors, and regulate matrix metalloproteases in tenocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If steroid injections are used to treat tendinopathy, then anti-inflammatory effect is achieved, but soft tissue damage and reduced muscle strength occur
Solution Approach 1:
The patent uses platelet-rich plasma (PRP) as an intermediary substance to deliver growth factors and anti-inflammatory mediators to the injured tendon tissue. Instead of directly injecting steroids that cause tissue damage, PRP serves as a natural carrier that releases bioactive components gradually, reducing harmful effects while maintaining therapeutic benefits
Solution Approach 2:
The patent employs autologous platelet-rich plasma, which is prepared from the patient's own blood. This self-service approach allows the body's own healing mechanisms to be activated through growth factors released from platelets, eliminating the need for external anti-inflammatory agents that may cause soft tissue damage
2Ease of operation
If surgical treatment is performed to relieve symptoms, then symptom relief is achieved, but fundamental regeneration does not occur
Solution Approach 1:
The patent applies platelet-rich plasma injection before or instead of surgical intervention to create a favorable healing environment. By delivering growth factors and inflammatory mediators in advance, the tendon tissue is prepared for regeneration, potentially avoiding surgery or reducing the need for invasive procedures
Solution Approach 2:
The patent activates the body's own regenerative capabilities by introducing concentrated platelets that release growth factors. This self-service mechanism promotes fundamental tendon regeneration rather than just temporary symptom relief, as the patient's own biological systems drive the healing process
3Ease of operation
If conservative treatments are used to treat tendinopathy, then treatment simplicity is maintained, but therapeutic effectiveness is limited
Solution Approach 1:
The patent changes the concentration and delivery parameters of growth factors by concentrating platelets in platelet-rich plasma. This parameter change transforms ordinary blood into a potent therapeutic agent that maintains the simplicity of injection administration while dramatically improving therapeutic effectiveness through concentrated bioactive components
Data Source
AI summary
Disclosed are a pharmaceutical composition containing isolated mitochondria as an effective component and uses of the composition. The pharmaceutical composition can restore the ATP synthesis capacity and antioxidant capacity of tenocytes damaged by inflammations to a normal tenocyte level. In addition, the pharmaceutical composition, when administered to damaged tenocytes, inhibits the expression of an apoptosis promoter, Bax, and increases the expression of an apoptosis inhibitor, Bcl-2. In addition, the pharmaceutical composition, when administered to damaged tenocytes, can restore the expression of MMP1 to a normal tenocyte level. Accordingly, uses of the pharmaceutical composition include prevention or treatment of tendinopathy in a subject.